ArticleDisease markers2016
Clinical Significance of Serum Interleukin-31 and Interleukin-33 Levels in Patients of Endometrial Cancer: A Case Control Study.
Article in Disease markers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Prognostic significance of IL-33 and ST2 expression in head and neck squamous cell carcinoma: a systematic review.Frontiers in oral health · 2025Pooled it
- Pooled it
- IL-31: State of the Art for an Inflammation-Oriented Interleukin.International journal of molecular sciences · 2022Pooled it
- Adipocytokines and disease progression in endometrial cancer: a systematic review.Cancer metastasis reviews · 2022Pooled it
- Immunomodulatory mediators IL-33, soluble ST2, IL-10, IFN-Frontiers in oral health · 2026Article
- Epigenetic regulation in gynecological cancers: a paradigm shift in immunotherapy strategies.Journal of experimental & clinical cancer research : CR · 2025Review
- The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLCBiomolecules · 2025Review
- Clinical Investigation of IL-31, TOS and GSH in the Sera of Gastric Cancer Females Patients In Iraq.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Clinical characteristics of endometrial cancers with microsatellite instability-high andFrontiers in oncology · 2025Article
- Interleukin-33 Expression on Treatment Outcomes and Prognosis in Brazilian Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.International journal of molecular sciences · 2023Article
- Interaction of S100A6 Protein with the Four-Helical Cytokines.Biomolecules · 2023Article
- Review
- The roles and clinical applications of interleukins in endometrial carcinoma.Frontiers in oncology · 2022Review
- Construction of an Immune-Autophagy Prognostic Model Based on ssGSEA Immune Scoring Algorithm Analysis and Prognostic Value Exploration of the Immune-Autophagy Gene in Endometrial Carcinoma (EC) Based on Bioinformatics.Journal of healthcare engineering · 2022Article
- Article
- Interleukin-31 Signaling Bridges the Gap Between Immune Cells, the Nervous System and Epithelial Tissues.Frontiers in medicine · 2021Review
- Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression.Nature communications · 2020Article
- IL-33/IL-31 Axis in Osteoporosis.International journal of molecular sciences · 2020Review
- The Use of Antibody Arrays in the Discovery of New Plasma Biomarkers for Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims. Previous evidence has proved that interleukin-31 (IL-31) and interleukin-33 (IL-33) can be potential markers in some cancers' formulation. We aimed to determine the potential role of IL-31 and IL-33 in prognosis of endometrial cancer patients. Methods. Serum samples were collected from 160 patients with endometrial cancer and 160 healthy controls. The ELISA kits (Raybio® Systems) specific for human IL-31 and human IL-33 were used. Serum levels of tumor markers (CEA, CA-125, and CA19-9) were measured by chemiluminescence immunoassay. A two-side P value < 0.05 was indicated to be significant. Results. Serum levels of IL-31 and IL-33 in patients were significantly elevated compared to those of healthy controls. The interleukin levels were also related to clinical characteristics, including tumor stages, depth of invasion, and existence of node metastases and distant metastases. The sensitivity and specificity of IL-31 and IL-33 were higher than the counterparts of tumor markers, both separately and in combination of IL-31, IL-33, and the clinical markers. Conclusions. This report is the first one mentioning the possible association between serum IL-31 and IL-33 and endometrial cancer. With their sensitivity and specificity, the interleukins may be useful biomarkers for endometrial cancer's prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.